Your tumor biology matters.

DecisionDx-Melanoma is a prognostic test for patients diagnosed with Stage I – III cutaneous melanoma. Our test looks at your tumor biology to predict the risk of your melanoma spreading or coming back.

Be your own advocate: Morgan England, stage III melanoma survivor, shares her story

As a Stage III Melanoma survivor, Morgan speaks on how important it is to be your own advocate. After her diagnosis, she requested the DecisionDx-Melanoma test from her doctor for the additional information it can provide. The results she received from her DecisionDx-Melanoma test report continue to help reduce her anxiety and provide confidence about her future.

With DecisionDx-Melanoma, you and your doctor can make informed decisions about:

  • 1

    Treatment

  • 2

    Follow-up appointments with your dermatologist

  • 3
    Additional visits with other specialties (referrals)
  • 4

    Surgical procedures such as a sentinel lymph node biopsy

Hear how physicians use DecisionDx-Melanoma

Aaron Farberg, MD describes how DecisionDx-Melanoma provides value for his patients

Why DecisionDx-Melanoma?

  • 150,000+

    Patients tested

  • ~50+

    of patients tested had a change in management1-3

  • 50+

    Strong evidence with 50+ published studies4

  • ~10

    Shown to detect recurrence approximately 10 months earlier in patients tested versus those untested5

The only prognostic test to be associated with improved patient survival4 and covered by Medicare.

Talk to your doctor to determine if the DecisionDx-Melanoma test is right for you.

References

  1. Berger et al. CMRO. 2016.
  2. Farberg et al. J Drugs Derm. 2017.  
  3. Dillon et al. CMRO. 2022.
  4. Bailey et al.  JCO PO. 2023. 
  5. Dhillon et al. Arch Dermatol Res. 2023.